{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Biomarkers&page=27", "query": { "intervention": "Serum Biomarkers", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 821, "total_pages": 83, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Biomarkers&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Biomarkers&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T13:12:51.314Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05077956", "title": "Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsing Multiple Sclerosis", "Multiple Sclerosis" ], "interventions": [ { "name": "Cerebrospinal and Blood Serum Semaphorin 4A Levels", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 0, "start_date": "2021-10-19", "completion_date": "2023-10-25", "has_results": false, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077956" }, { "nct_id": "NCT03835533", "title": "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "NKTR-214 (Cohort A)", "type": "DRUG" }, { "name": "Nivolumab (Cohort A, B and C)", "type": "DRUG" }, { "name": "Stereotactic body radiation therapy (SBRT) (Cohort B)", "type": "RADIATION" }, { "name": "CDX-301 (Cohort B and C)", "type": "DRUG" }, { "name": "Poly-ICLC (Cohort B)", "type": "DRUG" }, { "name": "INO-5151 (Cohort C)", "type": "DRUG" }, { "name": "Cellectra 2000", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "RADIATION", "DEVICE" ], "sponsor": "Parker Institute for Cancer Immunotherapy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 43, "start_date": "2019-06-21", "completion_date": "2022-10-03", "has_results": true, "last_update_posted_date": "2024-04-12", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • New York, New York + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03835533" }, { "nct_id": "NCT03401853", "title": "Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-03-23", "completion_date": "2024-09-19", "has_results": true, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03401853" }, { "nct_id": "NCT05686369", "title": "A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Celiac Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Chugai Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2023-03-08", "completion_date": "2023-10-05", "has_results": false, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 1, "location_summary": "Culver City, California", "locations": [ { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05686369" }, { "nct_id": "NCT03525925", "title": "Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 16, "start_date": "2018-07-18", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03525925" }, { "nct_id": "NCT02631746", "title": "Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Adult T-Cell Leukemia/Lymphoma", "Adult T-Cell Leukemia/Lymphoma", "Chronic Adult T-Cell Leukemia/Lymphoma", "HTLV-1 Infection", "Lymphomatous Adult T-Cell Leukemia/Lymphoma", "Smoldering Adult T-Cell Leukemia/Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pharmacogenomic Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-02-23", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2025-03-14", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Bethesda, Maryland • The Bronx, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631746" }, { "nct_id": "NCT00897494", "title": "Identification of Biomarkers for Early Detection of Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "mass spectrometry", "type": "OTHER" }, { "name": "surface-enhanced laser desorption/ionization-time of flight mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 75, "start_date": "2005-02", "completion_date": "2011-04", "has_results": false, "last_update_posted_date": "2016-03-09", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897494" }, { "nct_id": "NCT00601718", "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "gene expression analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "GENETIC" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-12", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-05-25", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00601718" }, { "nct_id": "NCT00255762", "title": "Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2005-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-28", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00255762" }, { "nct_id": "NCT03373188", "title": "VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Carcinoma Metastatic in the Liver", "Colorectal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma", "Stage I Pancreatic Cancer", "Stage IA Pancreatic Cancer", "Stage IB Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage IIA Pancreatic Cancer", "Stage IIB Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Colorectal Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Anti-SEMA4D Monoclonal Antibody VX15/2503", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-12-15", "completion_date": "2021-10-28", "has_results": false, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-10-16T13:12:51.314Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Rochester, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373188" } ] }